You can find the annual or quarterly income statement of China SXT Pharmaceuticals Inc here for insights into the performance and operational efficiency of China SXT Pharmaceuticals Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026H2
FY2025H1
FY2024H2
FY2024H1
FY2023H2
FY2023H1
FY2022H2
FY2022H1
FY2021H2
FY2021H1
FY2020H2
FY2020H1
FY2019H2
FY2019H1
FY2018Q4
FY2017Q4
Total revenue
-43.88%511.48K
-11.72%829.49K
29.54%988.91K
-22.24%939.58K
-51.52%763.39K
17.58%1.21M
71.70%1.57M
-73.38%1.03M
-52.90%917.07K
20.07%3.86M
-37.07%1.95M
-17.93%3.22M
--3.09M
--3.92M
24.40%1.43M
--1.15M
Revenue
-43.88%511.48K
-11.72%829.49K
29.54%988.91K
-22.24%939.58K
-51.52%763.39K
17.58%1.21M
71.70%1.57M
-73.38%1.03M
-52.90%917.07K
20.07%3.86M
-37.07%1.95M
-17.93%3.22M
--3.09M
--3.92M
24.40%1.43M
--1.15M
Cost of revenue
-46.30%364.50K
6.68%694.74K
69.47%723.28K
-41.78%651.24K
-34.03%426.80K
58.96%1.12M
-28.00%646.92K
-32.31%703.72K
-17.02%898.46K
-24.44%1.04M
-6.77%1.08M
11.04%1.38M
--1.16M
--1.24M
16.52%620.68K
--532.70K
Operating expenses
-56.14%1.30M
-85.73%1.47M
-211.96%-5.84M
336.19%10.29M
34.80%5.22M
-39.82%2.36M
-9.47%3.87M
45.33%3.92M
39.46%4.28M
-21.51%2.70M
15.68%3.07M
32.62%3.44M
--2.65M
--2.59M
75.87%1.13M
--644.04K
Depreciation, depletion, and amortization
202.14%41.57K
-33.30%68.54K
-28.32%100.50K
-6.56%102.75K
4.62%140.20K
-40.88%109.97K
-17.53%134.01K
1.68%186.00K
-18.06%162.49K
36.98%182.93K
--198.30K
--133.54K
----
----
103.83%29.75K
--14.60K
Operating profit
61.61%-784.01K
93.17%-638.27K
253.33%6.83M
-712.64%-9.35M
-93.94%-4.46M
60.21%-1.15M
31.62%-2.30M
-348.45%-2.89M
-199.98%-3.36M
627.20%1.16M
-353.16%-1.12M
-116.64%-220.75K
--442.56K
--1.33M
-40.89%300.05K
--507.65K
Net non-operating interest income (expenses)
Non-operating interest income
----
--17.00
--9.10K
----
----
242.03%236.00
-99.99%182.00
-99.83%69.00
--1.77M
--40.65K
----
----
----
----
----
----
Non-operating interest expense
----
-24.05%94.04K
99.76%136.79K
69.88%123.81K
875.47%68.48K
--72.88K
-98.84%7.02K
-100.00%0.00
--604.00K
--298.14K
----
----
----
----
----
----
Gains from sale of securities
----
58.42%-88.45K
-233.43%-80.06K
31.75%-212.71K
19.76%-24.01K
---311.64K
98.72%-29.93K
100.00%0.00
---2.34M
---184.59K
----
----
----
----
----
----
Special income (expenses)
94.64%-53.95K
----
-21.05%-422.92K
----
---349.39K
----
--0.00
----
100.00%0.00
----
---5.63M
----
----
----
----
----
Other non-operating income (expenses)
2.01%1.03M
271.15%18.17K
-14.01%394.50K
-126.46%-10.62K
249.44%458.78K
-68.01%40.12K
-1241.00%-307.00K
-85.98%125.41K
79.53%-22.89K
2249.18%894.54K
-497.69%-111.85K
3969.82%38.08K
--28.13K
---984.00
-325.53%-12.05K
--5.34K
Income before tax
106.55%163.72K
91.72%-802.57K
248.59%6.60M
-548.74%-9.70M
-68.07%-4.44M
45.97%-1.49M
42.03%-2.64M
-271.14%-2.77M
43.29%-4.56M
168.68%1.62M
-1831.95%-8.04M
-277.27%-2.35M
--464.01K
--1.33M
-42.62%286.73K
--499.75K
Income tax
--0.00
--0.00
----
----
-100.00%0.00
-100.00%0.00
100.55%2.37K
38.62%325.78K
-342.95%-427.70K
4649.28%235.02K
-20.43%-96.56K
-101.55%-5.17K
---80.17K
--332.41K
-16.07%104.86K
--124.94K
Income after tax
106.55%163.72K
91.72%-802.57K
248.59%6.60M
-548.74%-9.70M
-67.92%-4.44M
51.66%-1.49M
35.97%-2.64M
-323.84%-3.09M
47.99%-4.13M
158.83%1.38M
-1559.04%-7.94M
-335.98%-2.35M
--544.18K
--995.05K
-51.48%181.87K
--374.81K
Net income from continuous operations
106.55%163.72K
91.72%-802.57K
248.59%6.60M
-548.74%-9.70M
-67.92%-4.44M
51.66%-1.49M
35.97%-2.64M
-323.84%-3.09M
47.99%-4.13M
158.83%1.38M
-1559.04%-7.94M
-335.98%-2.35M
--544.18K
--995.05K
-51.48%181.87K
--374.81K
Net income attributable to controlling interests
106.55%163.72K
91.72%-802.57K
248.59%6.60M
-548.74%-9.70M
-67.92%-4.44M
51.66%-1.49M
35.97%-2.64M
-323.84%-3.09M
47.99%-4.13M
158.83%1.38M
-1559.04%-7.94M
-335.98%-2.35M
--544.18K
--995.05K
-51.48%181.87K
--374.81K
Net income attributable to common shareholders
106.55%163.72K
91.72%-802.57K
248.59%6.60M
-548.74%-9.70M
-67.92%-4.44M
51.66%-1.49M
35.97%-2.64M
-323.84%-3.09M
47.99%-4.13M
158.83%1.38M
-1559.04%-7.94M
-335.98%-2.35M
--544.18K
--995.05K
-51.48%181.87K
--374.81K
Basic earnings per share
100.18%22.36
98.72%-1.99
152.00%42.79
-32.37%-154.68
79.74%-82.30
85.31%-116.86
61.86%-406.17
-291.05%-795.36
77.59%-1.06K
125.18%416.32
-1253.48%-4.75K
-307.68%-1.65K
--412.00
--796.00
-51.46%122.56
--252.48
Diluted earnings per share
100.18%22.36
98.72%-1.99
152.00%42.79
-32.37%-154.68
79.74%-82.30
85.31%-116.86
61.86%-406.17
-291.05%-795.36
77.59%-1.06K
125.18%416.32
-1253.48%-4.75K
-307.68%-1.65K
--412.00
--796.00
-51.46%122.56
--252.48
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
FAQs
How do I read China SXT Pharmaceuticals Inc's income statement on TradingKey?
Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.
What is the difference between quarterly and annual income statements?
A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.
What does YOY mean on the income statement page?
YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.
Which income statement metrics matter most when analyzing SXTC stock?
Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.
What was China SXT Pharmaceuticals Inc's revenue at year end?
China SXT Pharmaceuticals Inc reported 1.14M in revenue for fiscal year 2025, up from 1.74M in the previous year.
How much revenue did China SXT Pharmaceuticals Inc report in the most recent quarter?
China SXT Pharmaceuticals Inc reported 511.48K in revenue for the most recent quarter, an increase of -43.88% year over year.
What was China SXT Pharmaceuticals Inc's net income for the year?
China SXT Pharmaceuticals Inc posted -6.21M in net income for fiscal year 2025.
How much net income did China SXT Pharmaceuticals Inc post in the last quarter?
China SXT Pharmaceuticals Inc reported 163.72K in net income for the latest quarter。
What was China SXT Pharmaceuticals Inc's annual operating profit?
China SXT Pharmaceuticals Inc's operating income was -1.67M for fiscal year 2025.
How is EPS related to the income statement?
EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.